Impairment of goodwill and adjustment of at-equity book value of minority interest in Envalior
- LANXESS impairs parts of its goodwill
- Adjustment of at-equity book value of minority interest in Envalior
- EBITDA pre exceptionals for Full Year 2023 remains within market expectations
Ad hoc according to Art. 17 paragraph 1 MAR
Cologne, February 27, 2024 – During the preparation of annual financial statements for the year 2023, LANXESS identified an impairment requirement on goodwill amounting to EUR 413 million. The impairment incurred in the Business Units Flavors & Fragrances and Polymer Additives and reduces the goodwill recognized as part of the acquisitions. The reason for the impairment is a demand that has partly developed weaker than expected in the respective Business Units, especially for the years 2023 and 2024.
In the course of the parallel and ongoing preparation of the financial statements at our joint venture Envalior, we also foresee the necessity of a material value reduction of our minority interest. This will likely result in a low to medium triple-digit million EUR amount.
The impairment analyses are not completed and not yet finally audited.
Neither the recognition of the impairment charges at LANXESS nor the reduction of the value of our minority interest have an effect on our EBITDA pre exceptionals, and are not cash relevant.
LANXESS will report its results for Full Year 2023 on 14 March 2024. EBITDA pre exceptionals is expected to be in line with market expectations. The consensus (Vara) for EBITDA pre exceptionals is currently at EUR 510 million.
Information for editors:
All global LANXESS news releases and their accompanying photos can be found at http://press.lanxess.com.
Recent photos of the Board of Management and other LANXESS image material are available at http://photos.lanxess.com.
